Author Archive for Pharmboy

The Medicines Company: Insider Buying

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

I'm seeing huge insider buying in the biotech company The Medicines Company (MDCO). The price has already moved up around 7%, but these buys are significant, in the millions of dollars range. ~ Ilene

 

 

 

Insider transaction table and buying vs. selling graphic above from insidercow.com.

Chart below from Yahoo.com





Epizyme – A Waiting Game

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Epizyme was founded in 2007, and trying to create drugs to treat patient's cancer by focusing on genetically-linked differences between normal and cancer cells. Cancer areas of focus include leukemia, Non-Hodgkin's lymphoma and breast cancer.  One of the Epizme cofounders, H. Robert Horvitz, won the Nobel Prize in Medicine in 2002 for "discoveries concerning genetic regulation of organ development and programmed cell death."

Before discussing the drug targets of Epizyme, understanding epigenetics is crucial to comprehend the company's goals.  

Genetic components are the DNA sequences that are 'inherited.'  Some of these genes are stronger than others in their expression (e.g., eye color).  Yet, some genes turn on or off due to external factors (environmental), and it is understanding the regulation of these genes that brings the term 'epigenetics.'  In other words, epigenetics does not have to be a nucleotide change in the DNA itself, but rather a functional regulation of the gene's expression.

Genes expression are controlled by many mechanisms, but Epizyme is focused on DNA methylation. DNA methylation is important for the regulation of gene expression, and functions normally to silence genes in genomic imprinting, X-chromosome inactivation, repressing repetative elements, aging, and cancer.  Two specific enzymes, DOT1L & EZH2 are the focus of the Company, and are DNA methylation enzymes (ie, Epizyme!!).  By inhibiting these two enzymes, cancer repressor genes will be turned on, and in conjunction with other chemotherapy agents, cancers may be repressed.

Early on, the Company raised $54M, and then GSK and Eisai signed up and pumped in $26M,  In May 2013, the Company went public for about $15 (5.9M shares at the time were sold), and shot out of the gate with a 50% premium the first day of trading to ~ $23.  The company was a darling.  While the company had two drugs in clinic, the compounds were very early on in clinical trials, but things were looking promising.   In Phase 1 data for their EZH2 inhibitor, tazemetostat, in genetically defined solid tumors of NHL, the overall response rate (ORR) was ~ 56% ((May 2015) which is very good!).  The phase 2 data…
continue reading





This Is Why Biotech Stocks May Explode Again

Reminder: Pharmboy and Ilene are available to chat with Members.

Here's an interesting article from Investor's Business Daily arguing that biotech stocks are beginning to recover from their recent declines, notwithstanding current weakness.

This Is Why Biotech Stocks May Explode Again

By 

Excerpt:

After a three-year bull run that more than quadrupled its value by its peak last July, IBD’s Medical-Biomed/Biotech Industry Group plunged 50% by early February, hurt by backlashes against high drug prices and mergers that seek to lower corporate taxes.

[...]

The group was up by even more before taking some hits over the past two weeks on negative earnings news from several industry players. But fund managers tell IBD the rebound is here. 

Why? For one, they say, the spate of bad news has already been factored into stock prices. But more than that, they see a climate favoring rejuvenated M&A, hot drugs in the new-product pipeline and pricing power for innovate products.

Bottom line: The positive factors that drove the runup never went away, they say. They just got drowned out by the noise.

“A very key point is that this group is a very high-beta group — particularly the small- to midcap stocks. Since they don’t have sales, they don’t have earnings,” said Tom Vandeventer, portfolio manager at Tocqueville Asset Management.

“The history of this group is that elevated macro uncertainty definitely hits (it),” Vandeventer said. “My own opinion is this group trades more on sentiment than on fundamentals during those time periods.”

Full article here >





Endo International plc – Ordinary Shares (ENDP) Collapses Taking Hedge Fund Returns With It

Reminder: Pharmboy and Ilene are available to chat with Members.

By Jacob Wolinsky. Originally published at ValueWalk.

Endo International plc – Ordinary Shares (ENDP) shares are crashing and when I say crashing I do not mean one percent or two percent or five percent or ten percent but at the time of this writing 38 percent. The biotech company is having a Valeant style crash and like Valeant ENDP is a big hedge fund hotel stock and it is likely killing returns for many, unless there is a big rebound soon.

Endo International plc - Ordinary Shares

Endo International plc – Ordinary Shares

As ZeroHedge notes (parenthesis ours):

The pain, however, is especially acute for a lot of hedge funds, because as Goldman reminds us after the spectacular blow ups of Valeant and Allergan, and recently, the plunge in uber hedge fund hotel AAPL, Endo itself is one of the stocks that has the highest hedge fund concentration in the S&P.

Endo International plc - Ordinary Shares

Endo International plc – Ordinary Shares

Who are these hedge funds? Most of the usual suspects including Visium (which is also having other issues), Viking Global (more pain), Paulson (shocker), Brahman, MSD and of course countless bank prop desks as listed below.

Endo International plc - Ordinary Shares

So if we report next week that the "smart money outflows" have continued for a record 15th week, we will know who the weekly scapegoat is for the latest redemption deluge as panicking hedge funds are forced to liquidate other assets to cover for their massive P&L blow ups in ENDP this morning.

Endo International plc – Ordinary Shares

The sell…
continue reading





Cantor Says Relypsa’s Veltassa Metrics Look Favorable

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Courtesy of Benzinga.

Positive Data Points For Veltassa Launch

Veltassa metrics look favorable so far, including a low payer rejection rate of ~20 percent, conversion from starter pack to prescriptions between 50 and 60 percent and in-line gross-to-net discount of approximately 25 percent.

Veltassa sales, albeit modest, were ahead of expectations. Veltassa sales came in at $0.6 million, compared to the 1Q16 estimate of $0.25 million. Relypsa had previously reported 1,155 outpatient prescriptions and 374 hospital/institution units sold in the quarter.

“Excluding gross-to-net discounts, sales would have been $0.8 million. Our expectation for 1H:16 has been modest, as we expect 2H:16, and in particular 4Q:16 to create visibility on Veltassa's sales potential,” analyst Mara Goldstein wrote.

Relypsa’s shares have come under pressure because investors may be viewing the debt financing as a major obstacle to a potential takeout of the company, Goldstein commented, while adding, “We continue to like the shares because of our view of the potential of Veltassa and hyperkalemia market overall.” She expects 3Q16 to be an inflection point for Veltassa, and could result in a realignment of valuation.

Latest Ratings for RLYP

Date Firm Action From To
May 2016 BTIG Research Maintains   Buy
May 2016 Cantor Fitzgerald Maintains   Buy
May 2016 Mizuho Securities Downgrades Neutral Underperform

View More Analyst Ratings for RLYP

View the Latest Analyst Ratings

Related
BTIG Cuts Veltassa Estimates, Relypsa's Price Target To $35
Mizuho Downgrades Relypsa, Says Near-Term Takeout 'Unlikely'
Relypsa's (RLYP) CEO John Orwin on Q1 2016 Results – Earnings Call Transcript (Seeking Alpha)

Posted-In: Cantor Fitzgerald Mara GoldsteinAnalyst Color Long Ideas Price Target Reiteration Analyst Ratings Trading Ideas





PRGO, VRX and the Papa of “Strong Shareholder Orientation”

Reminder: Pharmboy and Ilene are available to chat with Members.

By Ilene 

Remember this? It was Monday. PRGO is down from around $130 to under $100 since I started following it LAST WEEK. That's down almost 25% in a week, and almost 50% in the last year. I commented: 

"Perrigo CEO Joseph Papa leaves Perrigo (PRGO) to lead Valeant (VRX) while PRGO issues a warning about missing earnings expectations. Not surprisingly, PRGO stock plummeted today. 

Robert Ingram, Chairman of the [Valeant] Board, stated, "The Board has conducted a thorough search process and believes that Joe is the ideal leader for Valeant at this time. He has a strong shareholder orientation, a background in science, and an unmatched track record of accomplishments, highlighted by his ability to lead companies through times of transition and drive excellence across commercial, manufacturing and R&D platforms. In addition, fostering an ethical culture and creating opportunities for professional development have always been high priorities for Joe, and we look forward to Joe's arrival at Valeant" (Valeant names Papa CEO after he resigns from Perrigo).

"Reuters reports that Mr. Shareholder Orientation became 'well-known on Wall Street last year when Dublin-based Perrigo rebuffed a $26 billion takeover by Mylan NV, the largest-ever hostile bid decided by a shareholder vote.' Perrigo's market cap has now dropped to around $14.2 billion [now $13.9 billion] — down over 18% today alone -- making Papa look foolish for rejecting that buyout offer."

So after successfully (but not intelligently) fighting a $26 billion hostile takeover bid from Mylan, Perrigo reports disappointing quarterly results and it "slashes its outlook" (Perrigo shares tumble as CEO leaves for Valeant, guidance cut again). The stock has been in free fall and Papa is described as having a "strong shareholder orientation" and an "ethical culture."

While many were congratulating VRX for recruiting Papa to be its CEO, Jim Cramer wrote,

Perrigo's (PRGO) heartbreaking. How could Joe Papa, the man who was so intertwined with Perrigo for so long, the man who came on Mad Money and argued there was so much more value to the company than the price Mylan put on it — some 80 points higher than where it went out —


continue reading





Sarepta Plunges 50% After FDA Rejects Key Drug

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Sarepta Plunges 50% After FDA Rejects Key Drug

Courtesy of ZeroHedge. View original post here.

2016 has been a tempestuous year for Serepta shareholders. From over $40 to just $10 and then the miracle ramp from february back to $25 before the writing on the wall ahead of last night's FDA decision and now – following yesterday's monstrous short-squeeze (36% surge), a 50% collapse to $8 – a 4 year low for yet another Biotech darling of old. This morning's collapse comes after the FDA voted that SRPT's muscular dystrophy drug was not effective

As Bloomberg reports,

An FDA advisory panel voted 7-3 with 3 abstentions that Sarepta’s single historically controlled study doesn’t provide substantial evidence that eteplirsen is effective for treatment of Duchenne muscular dystrophy (DMD).

Some panel members raised questions about study design, said more data are needed.

Not a great morning for Stevie Cohen who just upped his stake (seems he did not get the nod this time)…

Any questions, refer to Christopher Marai or Chad Messer (PhD!)…





Perrigo Company plc (PRGO) Tanks As CEO Leaves For Valeant (VRX)

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Perrigo Company plc (PRGO) Tanks As CEO Leaves For Valeant (VRX)

By Jacob Wolinsky. Originally published at ValueWalk.

Perrigo Company plc (PRGO) Tanks As CEO Leaves For Valeant (VRX) – it was a decent day to be a VRX shareholder and a bad day to be a PRGO and if your initials are JP it was a really bad day … being shareholders of both companies. As JPMorgan notes: This morning, Perrigo announced the appointment of John Hendrickson (former President) as CEO, replacing Joe Papa who is set to become the CEO of Valeant. The company also provided disappointing preliminary 1Q results and significantly lowered full year 2016 EPS to $8.20-$8.60 (vs. prior range of $9.50-$9.80) due to Rx pricing pressure, continued underperformance of the Branded Consumer business, and lower expectations for new product launches.

Perrigo Company plc CEO leaves for VRX analysts react

RBC

There will be several who focus on recent challenges and the need for someone from the outside to come in and help turn PRGO around. But on the other hand, John Hendrickson has been with PRGO since 1989 and led key operations including VP of Manufacturing to EVP and General Manager of Consumer Health to its current President among others and this should minimize any disruption at a time where operational focus is critical. He also understands the Consumer Health business well which is the highest value part of PRGO’s business. PRGO also mentioned that Omega head Marc Coucke’s Board nomination has been withdrawn by the nominating and governance committee.

Morgan Stanley

New CEO has strong experience at Perrigo Company plc. Mr. John Hendrickson has served as President of PRGO since October 2015, following his prior roles as EVP, Global Operations & Supply Chain (2006 -2015) and the head of US Consumer Healthcare (2003-2006). A 27-year veteran at Perrigo, he joined the company in 1989. With the resignation of current Chairman and CEO Joseph Papa, the role of Chairman will now be separated from the CEO role. The board has elected Independent Director Laurie Brlas as PRGO new Chairman.

Goldman Sachs

PRGO announced the resignation of former CEO Joe Papa and promotion of former President John Hendrickson as new CEO. Mr. Hendrickson has been at PRGO since 1989 in various roles including leading the US Consumer…
continue reading





The Michael Pearson Era Is Officially Over: Valeant Appoints Joseph Papa As Chairman And CEO

Reminder: Ilene and Pharmboy are available to chat with Members, comments are found below each post.

Perrigo CEO Joseph Papa leaves Perrigo (PRGO) to lead Valeant (VRX) while PRGO issues a warning about missing earnings expectations. Not surprisingly, PRGO stock plummeted today. 

Robert Ingram, Chairman of the [Valeant] Board, stated, "The Board has conducted a thorough search process and believes that Joe is the ideal leader for Valeant at this time.  He has a strong shareholder orientation, a background in science, and an unmatched track record of accomplishments, highlighted by his ability to lead companies through times of transition and drive excellence across commercial, manufacturing and R&D platforms.  In addition, fostering an ethical culture and creating opportunities for professional development have always been high priorities for Joe, and we look forward to Joe's arrival at Valeant" (Valeant names Papa CEO after he resigns from Perrigo).

Reuters reports that Mr. Shareholder Orientation became "well-known on Wall Street last year when Dublin-based Perrigo rebuffed a $26 billion takeover by Mylan NV, the largest-ever hostile bid decided by a shareholder vote." Perrigo's market cap has now dropped to around $14.2 billion — down over 18% today alone -- making Papa look foolish for rejecting that buyout offer.

Papa’s departure comes just months after he successfully beat back a $26 billion hostile takeover bid from Mylan [MYL] spearheading a campaign that ultimately persuaded shareholders to reject Mylan’s bid.

Since then, though, Perrigo has reported disappointing quarterly results and slashed its outlook. (Perrigo shares tumble as CEO leaves for Valeant, guidance cut again)

Papa's recent record at PRGO reveals not only bad judgment but also, more disturbing, a lack of ordinary CEO loyalty. As Jim Cramer writes,

Perrigo's (PRGO) heartbreaking. How could Joe Papa, the man who was so intertwined with Perrigo for so long, the man who came on Mad Money and argued there was so much more value to the company than the price Mylan put on it — some 80 points higher than where it went out — just leave for Valeant (VRX)? How could he leave with a huge shortfall and some weird impairment charge about an acquisition that Papa crowed about, Omega, as a way to get international exposure?

There wasn't a single


continue reading





Perrigo: BTFD – Times Two?

Reminder: Ilene is available to chat with Members, comments are found below each post.

Update: PRGO may be losing its CEO to Valeant: Valeant’s Latest Acquisition Target: Perrigo’s CEO?. This news is knocking the price down into the low $120s. Paul says he is buying more shares and selling 2018 puts with a strike price of $150. See the screenshot below. Paul sold those three 2018 $150 puts.

Paul writes, "A forced change at the CEO level and PRGO’s depressed share price might induce management to reconsider its refusal to sell at above $200 when Mylan came calling last year. Shareholders are unhappy meaning something is likely being planned to get the stock moving again."

Updated chart:

As originally posted April 20, 2016. 

On June 10, 2015, Paul Price gave us a trade idea on BAX. Baxter Int. (BAX) was trading at around $66/share and scheduled to split off Baxalta (BXLT), its BioScience division, in the ratio of one share of BXLT for each share of BAX. BXLT is now at $40.65 and BAX is at $43.40. 

Baxter Int. (BAX) is splitting off its BioSciences division into a new company called Baxalta. Shares of Baxalta will be given as a tax-free dividend, in the ratio of one to one, to BAX holders on record on June 17, 2015. 

If you bought BAX, and held both companies after the split, till today, you'd have about a 27% gain. (Both Phil and Paul also suggested selling puts, see the article for more details.)

Now, for about a month, Paul's been suggesting buying and/or selling puts on Perrigo (PRGO, $129) at TheStreet.com's Real Money Pro (paywall) and Guru Focus. PRGO has been languishing around $128 – 130 and he thinks this area makes a good entry point for a longer term trade. Here are several excerpts from Paul's recent article at Real Money Pro with some updated charts. 

Healthcare products provider Perrigo (PRGO) has a fabulous long-term record. The stock dropped sharply on Feb. 18, 2016, as the firm took a charge in its latest quarter for costs associated with fighting off a hostile takeover attempt from Mylan (MYL). 


continue reading





 
 
 

Zero Hedge

Huge 300,000 Bpd Fracklog Could Derail Oil Price Recovery

Courtesy of ZeroHedge. View original post here.

Authored by Nick Cunningham via OilPrice.com,

Thousands of drilled shale wells are sitting idle, unfracked and uncompleted.

The backlog of drilled but uncompleted wells (DUCs) grew dramatically beginning in 2014, as low oil prices forced drillers to hold off on completion in hopes of higher prices at a later date. After all, why bring production online in a low price environment when the same oil could earn more in the future if prices rebound. Tha...



more from Tyler

ValueWalk

How Much Of Your State's Debt Rests On Your Shoulders

By HowMuch. Originally published at ValueWalk.

Uncle Sam is not the only one who can raise taxes and borrow money on your behalf. Those powers also belong to each and every state in the Union – and they all exercise them. Which means that as Americans you not only shoulder the weight of the federal debt (your share: about $42,500), but also carry the burden of your state’s IOUs. That burden varies per state of course, and the spread is very wide indeed, as shown by this graph, based on data released last month by the Tax Foundation.

States are shown bigger and closer to the center if their debt is higher. Red state...



more from ValueWalk

Phil's Favorites

PhilStockWorld.com Weekly Trading Webinar

 

PhilStockWorld.com Weekly Trading Webinar - 03-29-17

For LIVE access on Wednesday afternoons, join us at Phil's Stock World – click here

Major Topics:

00:02:31 Government Security
00:06:49 Checking on the Markets
00:08:40 Macy's Charts
00:08:53 Long-Term Portfolio
00:17:29 Short-Term Portfolio
00:21:06 5% Portfolio
00:31:15 XON
00:33:49 Trade Ideas
00:37:05 ETP
00:39:48 Cecking on the Markets
00:43:22 Energy Transfer Partners: Dakota Access Pipeline
00:47:36 CHK Charts and Trade Ideas
00:54:24 WYNN
01:01:45 WYNN Trade Ideas
01:09:53 TSLA
01:17:25 Petroleum Status Report
01:22:47 $WTIC
01:24:50 Petroleum Status Report
01:32:24 Peak Oil...



more from Ilene

Kimble Charting Solutions

Energy Sector; Two Thirds chance they rally here

Courtesy of Chris Kimble.

Below looks at the performance of the S&P 500 Sectors, looking back 5-years. The winner for the lowest performance is the Energy Sector (-1.42%). XLE is lagging the S&P 500 by almost 70%, in just 5-years. “Time for them to rally?”

CLICK ON CHART TO ENLARGE

Below looks at the Energy ETF (XLE)/S&P 500 ratio over the past 17-years and why we find this pattern worth looking closer into.

...



more from Kimble C.S.

Chart School

SP500 Kitchin cycle says trouble brewing

Courtesy of Read the Ticker.

Since March 2009 the SP500 is up 250%, so another 10% gain is just chump change, and chasing it may be a step too far!

The Kitchin cycle (purple loops) suggests trouble can be expected between May 2017 and June 2018, readtheticker.com suggests a minimum 20% correction is a sure thing during the next 18 months with the TRUMP'ster around. Why chase a 10% gain now? Best waiting for the expected market correction before increasing your exposure to real market risk. Makes sense no!

NOTE: The price chart below with our RTTHurstDPO indicator shows price is conforming to the 900 bar Kitchin cycle.

Click for popup. Clear your browser cache if image is not showing.


O...

more from Chart School

Market News

News You Can Use From Phil's Stock World

 

Financial Markets and Economy

Wall Street posts sharp gains, fueled by strong consumer data (Reuters)

U.S. stocks ended sharply higher on Tuesday, with financial and energy shares surging as data showed U.S. consumer confidence soaring to a more than 16-year high.

If Stocks Wobble, Will Bonds Be There To Absorb the Blow? (The Wall Street Journal)

If stocks are hitting a sticky patch, are bonds bound to shine? That was certainly the case in the first half of last year, when sharp falls in equity markets helped push bond prices sky-high. But the backdrop is different this time around.

...



more from Paul

OpTrader

Swing trading portfolio - week of March 27th, 2017

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Members' Corner

More Natterings

Courtesy of The Nattering Naybob

[Click on the titles for the full articles.]

A Quick $20 Trick?

Summary

Discussion, critique and analysis of the potential impacts on equity, bond, commodity, capital and asset markets regarding the following:

  • Last time out, Sinbad The Sailor, QuickLogic.
  • GlobalFoundries, Jha, Smartron and cricket.
  • Quick money, fungible, demographics, QUIK focus.

Last Time Out

Monetary policy is just one form of policy that effects capital,...



more from Our Members

Digital Currencies

Bitcoin Tumbles Below Gold As China Tightens Regulations

Courtesy of Zero Hedge

Having rebounded rapidly from the ETF-decision disappointment, Bitcoin suffered another major setback overnight as Chinese regulators are circulating new guidelines that, if enacted, would require exchanges to verify the identity of clients and adhere to banking regulations.

A New York startup called Chainalysis estimated that roughly $2 billion of bitcoin moved out of China in 2016.

As The Wall Street Journal reports, the move to regulate bitcoin exchanges brings assurance that Chinese authorities will tolerate some level of trading, after months of uncertainty. A draft of the guidelines also indicates th...



more from Bitcoin

Mapping The Market

Congress begins rolling back Obama's broadband privacy rules

Courtesy of Jean Luc

I am trying to remember who on this board said that people wanted to Trump because they want their freedom back. Well….

Congress begins rolling back Obama's broadband privacy rules

By Daniel Cooper, Endgadget

ISPs will soon be able to sell your most private data without your consent.

As expected, Republicans in Congress have begun the process of rolling back the FCC's broadband privacy rules which prevent excessive surveillance. Arizona Republican Jeff Flake introduced a resolution to scrub the rules, using Congress' powers to invalidate recently-approved federal regulations. Reuters reports that the move has broad support, with 34 other names throwing their weight behind the res...



more from M.T.M.

Promotions

Free eBook - "My Top Strategies for 2017"

 

 

Here's a free ebook for you to check out! 

Phil has a chapter in a newly-released eBook that we think you’ll enjoy.

In My Top Strategies for 2017, Phil's chapter is Secret Santa’s Inflation Hedges for 2017.

This chapter isn’t about risk or leverage. Phil present a few smart, practical ideas you can use as a hedge against inflation as well as hedging strategies designed to assist you in staying ahead of the markets.

Some other great content in this free eBook includes:

 

·       How 2017 Will Affect Oil, the US Dollar and the European Union

...

more from Promotions

Biotech

The Medicines Company: Insider Buying

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

I'm seeing huge insider buying in the biotech company The Medicines Company (MDCO). The price has already moved up around 7%, but these buys are significant, in the millions of dollars range. ~ Ilene

 

 

 

Insider transaction table and buying vs. selling graphic above from insidercow.com.

Chart below from Yahoo.com

...

more from Biotech

All About Trends

Mid-Day Update

Reminder: Harlan is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David



FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>